Truist analyst Richard Newitter raised the firm’s price target on Procept BioRobotics to $50 from $48 and keeps a Buy rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRCT:
- PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
- Procept BioRobotics price target lowered to $55 from $60 at B. Riley
- Procept BioRobotics raises FY23 revenue view to $133.5M from $131M
- Procept BioRobotics reports Q3 EPS (51c), consensus (53c)
- PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
Questions or Comments about the article? Write to editor@tipranks.com